Metabolic syndrome and the risk of urothelial carcinoma of the bladder: A case-control study

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Montella, Maurizio ^a   Di Maso, Matteo ^b   Crispo, Anna ^a   Grimaldi, Maria ^a   Bosetti, Cristina ^c   Turati, Federica ^d   Giudice, Aldo ^a   Libra, Massimo ^e   Serraino, Diego ^b   La Vecchia, Carlo ^f   Tambaro, Rosa ^a   Cavalcanti, Ernesta ^a   Ciliberto, Gennaro ^a   Polesel, Jerry ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e UNIVERSITY OF CATANIA   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

Author keywords

Bladder cancer; Diabetes; Metabolic syndrome; Obesity

Indexed keywords

ABDOMINAL OBESITY; ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PROSPECTIVE STUDY; SMOKING; CARCINOMA; COMPLICATION; ITALY; MIDDLE AGED; OBESITY, ABDOMINAL; PATHOLOGY; RISK FACTOR; URINARY BLADDER NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CASE-CONTROL STUDIES; DIABETES MELLITUS; FEMALE; HUMANS; HYPERTENSION; ITALY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY, ABDOMINAL; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 84944445486     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1769-9     Document Type: Article

References (34)

1. Murta-Nascimento C, Schmitz-Drager BJ, Zeegers MP, Steineck G, Kogevinas M, Real FX, et al. Epidemiology of urinary bladder cancer: from tumor development to patient's death. World J Urol. 2007;25:285-95.
2. Babjuk M, Burger M, Zigeuner R, Shariat SF, Van Rhijn BW, Compérat E, et al. European Association of Urology. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013;64:639-53.
3. Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Pineros M, et al. Cancer Incidence in Five Continents, Vol. X IARC Sci Pub, Lyon, 2013.
4. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011;306:737-45.
5. Qin Q, Xu X, Wang X, Zheng XY. Obesity and risk of bladder cancer: a meta-analysis of cohort studies. Asian Pac J Cancer Prev. 2013;14:3117-21.
6. Stocks T, Bjorge T, Ulmen H, Manjer J, Häggström C, Nagel G, et al. Metabolic risk score and cancer risk: pooled analysis of seven cohorts. Int J Epidemiol. 2015;44:1353-63.
7. Cantiello F, Cicione A, Salonia A, Autorino R, De Nunzio C, Briganti A, et al. Association between metabolic syndrome, obesity, diabetes mellitus and oncological outcomes of bladder cancer: A systematic review. Int J Urol. 2015;22:22-32.
8. Kassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome: definition and controversies. BMC Med. 2011;9:48.
9. Esposito K, Capuano A, Giugliano D. Metabolic Syndrome and cancer: holistic or reductionist? Endocrine. 2014;45:362-4.
10. Rosato V, Zucchetto A, Bosetti C, Dal Maso L, Montella M, Pelucchi C, et al. Metabolic syndrome and endometrial cancer risk. Ann Oncol. 2011;22:884-9.
11. Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer. Diabetes Care. 2012;35:2402-11.
12. Turati F, Talamini R, Pelucchi C, Polesel J, Franceschi S, Crispo A, et al. Metabolic syndrome and hepatocellular carcinoma risk. Br J Cancer. 2013;108:222-8.
13. Polesel J, Bosetti C, Di Maso M, Montella M, Libra M, Garbeglio A, et al. Tobacco smoking and the risk of papillary and non-papillary transitional cell carcinoma of the bladder. Cancer Causes Control. 2014;25:1151-8.
14. Bosetti C, Tavani A, Negri E, Trichopoulos D, La Vecchia C. Reliability of data on medical conditions, menstrual and reproductive history provided by hospital controls. J Clin Epidemiol. 2001;54:902-6.
15. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation task force on epidemiology and prevention; Nationale Heart, Lung, and Blood Institute; American Heart Association; World Heart Association; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-45.
16. Breslow NE, Day NE. Statistical methods in cancer research, Vol. 1. The analysis of case-control studies. IARC Sci Publ. 1980;32:5-338.
17. Pelucchi C, Serraino D, Negri E, Montella M, Dellanoce C, Talamini R, et al. The metabolic syndrome and risk of prostate cancer in Italy. Ann Epidemiol. 2011;21:835-41.
18. Haggstrom C, Stocks T, Rapp K, Bjørge T, Lindkvist B, Concin H, et al. Metabolic syndrome and risk of bladder cancer; prospective cohort study in the metabolic syndrome and cancer project (Me-can). Int J Cancer. 2011;128:1890-8.
19. Russo A, Autelitano M, Bisanti L. Metabolic syndrome and cancer risk. Eur J Cancer. 2008;44:293-7.
20. Janssen I, Katzmarzyk PT, Ross R. Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr. 2004;79:379-84.
21. Holick CN, Giovannucci EL, Stampfer MJ, Michaud DS. Prospective study of body mass index, heigth, physical activity and incidence of bladder cancer in US men and women. Int J Cancer. 2007;120:140-6.
22. Koebnick C, Michaud D, Moore SC, Park Y, Hollenbeck A, Ballard-Barbash R, et al. Body mass index, physical activity, and bladder cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev. 2008;17:1214-21.
23. Matsushita Y, Nakagawa T, Shinohara M, Yamamoto S, Takahashi Y, Mizoue T, et al. How can waist circumference predict the body composition? Diabetol Metab Synder. 2014;6:11.
24. Cantiello F, Cicione A, Autorino R, Salonia A, Briganti A, Ferro M, et al. Visceral obesity predicts adverse pathological features in urothelial bladder cancer patients undergoing radical cystectomy: a retrospective cohort study. World J Urol. 2014;32:559-64.
25. Cirillo D, Rachiglio AM, La Montagna R, Giordano A, Normanno N. Leptin signaling in breast cancer: an overview. J Cell Biochem. 2008;105:956-64.
26. Beckman KB, Ames BN. Oxidative decay of DNA. J Biol Chem. 1997;272:19633-6.
27. Newton CC, Gapstur SM, Campbell PT, Jacobs EJ. Type 2 diabetes mellitus, insulin-use and risk of bladder cancer in a large cohort study. Int J Cancer. 2013;132:2186-91.
28. Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia. 2006;49:2819-23.
29. Tseng CH. Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia. 2011;54:2009-15.
30. MacKenzie T, Zens MS, Ferrara A, Schned A, Karagas MR. Diabetes and risk of bladder cancer: evidence from a case-control study in New England. Cancer. 2011;117:1552-56.
31. Prizment AE, Anderson KE, Yuan JM, Folsom AR. Diabetes and risk of bladder cancer among postmenopausal women in the Iowa Women's Health Study. Cancer Causes Control. 2013;24:603-8.
32. Stocks T, Rapp K, Bjørge T, Manjer J, Ulmer H, Selmer R, et al. Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Med. 2009;6:e1000201.
33. Bario-Lopez MT, Bes-Rastrollo M, Beunza JJ, Fernandez-Montero A, Garcia-Lopez M, Martinez-Gonzalez MA. Validation of metabolic syndrome using medical records in the SUN cohort. BMC Public Health. 2011;11:867.
34. Vargas CM, Burt VL, Gillum RF, Pamuk ER. Validity of self-reported hypertension in the National Health and Nutrition Examination Survey III, 1988-1991. Prev Med. 1997;26:678-85.